CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 7 enrolled
Drug / intervention
CCX168drug
Likely dose
CCX168 30 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02384317
NCT02384317Phase 2Completed
CompareCT.gov

An Open-Label Phase 2 Study to Evaluate the Safety and Efficacy of CCX168 in Subjects With Immunoglobulin A Nephropathy on Stable RAAS Blockade

Amgen·interventional·Posted Mar 10, 2015·Updated Mar 13, 2025

In Brief

A Phase 2 clinical trial evaluating CCX168 for Immunoglobulin A Nephropathy. Completed, enrolled 7 participants across 6 sites in 2 countries.

Detailed Summary

The primary safety objective of this study is to evaluate the safety and tolerability of CCX168 in subjects with IgAN on background supportive therapy with a maximally tolerated dose of RAAS blockade. The primary efficacy objective is to evaluate the efficacy of CCX168 based on an improvement in proteinuria.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsImmunoglobulin A Nephropathy
CountriesSweden, United States
Collaborators--

Timeline

Phase 2CompletedFinished
201520162017201820192020202120222023202420252026
First PostedMar 10, 2015
Enrollment StartMar 27, 2015
Primary CompletionSep 13, 2015
Study CompletionJun 1, 2018
TodayJul 2, 2026
Enrollment to primary: 6 monthsPosted 11.3 years ago

Interventions

CCX168drug

CCX168 30 mg, twice daily (b.i.d.) orally for 84 days (12 weeks). The CCX168 dose was taken in the morning, optimally within one hour after breakfast, and in the evening, optimally within one hour after dinner.